|
| Systematic evaluation and meta analysis of efficacy and safety of Danhong Injection in the treatment of acute cerebral infarction |
| Hits 498 Download times 284 Received:July 23, 2022 |
| View Full Text View/Add Comment Download reader |
| DOI
10.11656/j.issn.1672-1519.2022.11.13 |
| Key Words
Danhong Injection;acute cerebral infarction;randomized controlled trial;system evaluation;Meta analysis |
| Author Name | Affiliation | E-mail | | HUANG Yifei | Heilongjiang University of Chinese Medicine, Harbin 150040, China | | | FENG Chaonan | Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | YIN Yanzhe | Heilongjiang University of Chinese Medicine, Harbin 150040, China | | | HU Haiyin | Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | | | WANG Hui | Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | wangh@tice.com.cn | | ZHANG Dong | Evidence-based Medicine Center, Tianjin University of Traditional Chinese Medicine, Tianjin 301617, China | zhangd@tice.com.cn |
|
| Abstract
|
| [Objective] To systematically evaluate the efficacy and safety of Danhong Injection in the treatment of acute cerebral infarction.[Methods] CNKI,Wanfang,VIP,SinoMed,PubMed and Embase databases were searched by computer from the time of database establishment to January 2022. Randomized controlled trials(RCTs) of Danhong Injection in the treatment of acute cerebral infarction were retrieved,and the quality of the included studies was evaluated using the bias risk assessment tool recommended by the Cochrane Systematic Review Manual,and the efficacy and safety of Danhong Injection were systematically evaluated.[Results] A total of 2 511 studies were retrieved,and 23 RCTS were eventually included,with a total of 3 169 patients. The data of the 23 studies were complete,but there was no trial registration,protocol approval,allocation concealment and subject blindness. The 15 of the studies only referred to "randomization" but did not describe specific grouping methods,and 2 only reported subjective outcome measures. Meta-analysis showed that clinical efficacy[RR=1.23(1.19,1.28),P<0.05],neurological deficit score (NIHSS)[MD=-3.64(-3.80,-3.47),P< 0.05],fibrinogen[MD=-0.83(-0.99,-0.68),P<0.05],the plasma viscosity[MD=-0.20(-0.27,-0.14),P<0.05],whole blood low shear viscosity[MD=-1.58(-1.90,-1.25),P<0.05],whole blood high shear viscosity[MD=-0.56(-0.69,-0.44),P<0.05],combined with Danhong Injection on the basis of conventional treatment of Western medicine was significantly better than conventional treatment of Western medicine. A total of 23 adverse reactions were reported in the included study,including 16 in the treatment group and 7 in the control group.[Conclusion] This study systematically evaluated the efficacy and safety of Danhong Injection in the treatment of acute cerebral infarction and the results showed that compared with conventional treatment alone,Danhong Injection combined with conventional treatment can improve the clinical efficacy of acute cerebral infarction. Due to the quantity and quality of the included literature,the research conclusions need to be verified by more high-quality RCT studies. |
|
|
|
|
|
|
|
